current
vaccin
base
variou
strategi
use
attempt
protect
pathogen
infect
among
formul
vaccin
adjuv
typic
increas
vaccin
effici
adjuv
recruit
antigenpres
cell
apc
dendrit
cell
dc
monocyt
stabil
vaccin
recent
newer
adjuv
develop
increas
vaccin
efficaci
especi
peptidebas
vaccin
besid
adjuv
develop
tolllik
receptor
tlr
agonist
also
induc
innat
immun
respons
prerequisit
effect
vaccin
sinc
discoveri
adjuv
peptidebas
vaccin
subunit
vaccin
conjug
vaccin
use
protein
antigen
coadminist
adjuv
despit
ongo
effort
year
number
current
approv
adjuv
minim
unit
state
five
adjuv
approv
alum
cpg
among
alum
approv
adjuv
use
human
squalenebas
adjuv
approv
europ
usa
use
influenza
vaccin
howev
alum
mainli
induc
immun
respons
induc
cellmedi
immun
respons
excel
adjuv
induc
antibodi
product
antigen
poorli
induc
cellmedi
immun
respons
moreov
fact
adjuv
licens
mean
entir
safe
case
alum
adjuv
problem
autoimmuneinflammatori
syndrom
induc
adjuv
asia
syndrom
found
multipl
sclerosi
system
lupu
erythematosu
chronic
fatigu
syndrom
squalenebas
adjuv
known
caus
chronic
arthriti
rat
induc
lupusrel
antinrnpsmsu
antibodi
mice
therefor
although
first
consider
develop
adjuv
increas
immunogen
crucial
consider
safeti
adjuv
immun
cell
human
facilit
specif
immun
respons
infect
differ
pathogen
bacteria
virus
receptor
respond
conserv
pathogenassoci
molecular
pattern
associ
bacteri
cell
wall
lipopolysaccharid
protein
viral
rnadna
receptor
known
patternrecognit
receptor
prr
tlr
typic
prr
tlr
agonist
highli
activ
innat
immun
respons
thu
tlr
agonist
develop
vaccin
adjuv
tlr
ligand
activ
antigen
present
macrophag
promot
dc
matur
upregul
mhc
class
turn
induc
cell
respons
among
sever
tlr
agonist
doublestrand
rna
dsrna
induc
innat
immun
respons
via
make
excel
tlrbase
adjuv
candid
exampl
poli
c
repres
dsrna
test
adjuv
howev
poli
c
induc
system
massiv
cytokin
releas
ie
cytokin
storm
result
excess
immun
respons
could
final
lead
advers
effect
furthermor
poli
iclc
poli
c
deriv
caus
sever
pulmonari
patholog
moreov
shown
dsrna
aggrav
renal
function
addit
sinc
immunolog
effect
differ
depend
length
poli
c
make
standard
difficult
poli
c
unsuit
use
adjuv
even
though
capabl
highli
induc
immun
respons
singlestrand
rna
ssrna
also
known
serv
agonist
retino
acidinduc
gene
rigi
induc
innat
immun
respons
increas
immunogen
compar
dsrna
ssrna
induc
appropri
immun
respons
remain
bodi
long
time
result
fewer
intens
advers
effect
current
ssrna
studi
intrins
adjuv
tumorvaccin
studi
recent
german
biotech
compani
curevac
ag
test
ssrna
nanostructur
adjuv
formul
disulfidecrosslink
cation
carrier
peptid
although
ssrna
clinic
approv
adjuv
addit
mani
research
intens
studi
potenti
use
ssrna
vaccin
adjuv
instanc
lou
et
al
found
ssrna
nanocomplex
adjuv
show
effici
target
lymph
node
induc
immun
edward
et
al
identifi
consist
adjuv
effect
sequenceengin
mrna
vaccin
vitro
human
vivo
mous
model
heidenreich
et
al
demonstr
strong
immunostimulatori
capac
novel
rnabas
adjuv
consid
ssrna
nanostructur
adjuv
might
eventu
appli
use
prophylact
vaccin
safeti
issu
especi
import
recent
develop
sever
ssrnaexpress
platform
among
select
rna
deriv
intern
ribosom
entri
site
ire
intergen
region
igr
cricket
paralysi
viru
crpv
ssrna
nanostructur
adjuv
express
desir
gene
vivo
vitro
elicit
strong
immun
respons
includ
innat
immun
respons
immun
respons
immun
mice
nonhuman
primat
crpv
igr
iresderiv
ssrna
proteinbas
vaccin
show
increas
product
antibodi
includ
indic
respons
indic
respons
neutral
antibodi
moreov
previous
found
crpv
igr
iresderiv
ssrna
cluster
size
nanostructur
atom
forc
microscopi
although
well
document
ssrna
nanostructur
function
immun
stimul
safeti
intens
studi
studi
verifi
safeti
new
ssrna
nanostructur
adjuv
varieti
way
herein
present
gener
toxic
profil
immunologicaltox
result
mice
ssrna
nanostructur
adjuv
design
use
igr
ire
latepolyadenyl
signal
sequenc
design
express
platform
ssrna
nanostructur
adjuv
four
restrict
enzym
sequenc
untransl
region
enabl
clone
multiclon
site
insert
variou
gene
vitro
transcript
perform
use
ez
high
yield
vitro
transcript
kit
enzynom
daejeon
korea
accord
manufactur
instruct
ssrna
purif
perform
use
licl
ssrna
concentr
evalu
use
nanodrop
spectrophotomet
thermo
fisher
scientif
usa
ssrna
integr
analyz
denatur
gel
electrophoresi
brief
structur
ssrna
adjuv
shown
figur
cell
deriv
human
foreskin
fibroblast
obtain
korean
cell
line
bank
seoul
korea
cell
cultur
dulbecco
modifi
eagl
medium
fetal
bovin
serum
fb
corn
ny
usa
gibco
ca
usa
cell
cultur
humidifi
incub
vitro
cellviabl
test
perform
bromid
mtt
assay
cell
seed
plate
densiti
cellswel
h
medium
without
fetal
bovin
serum
replac
ssrna
nanostructur
adjuv
poli
c
ad
well
cell
viabil
determin
differ
time
point
h
perform
mtt
assay
viabil
cell
well
measur
term
optic
densiti
wavelength
nm
use
micropl
reader
promega
wi
usa
sixweekold
balbc
mice
purchas
daehan
biolink
co
seoul
korea
mice
quarantin
acclim
week
initi
studi
evalu
health
statu
mice
hous
cathol
univers
korea
specificpathogenfre
condit
lightdark
cycl
temperatur
rel
humid
anim
handl
accord
protocol
approv
cathol
univers
korea
june
anim
facil
cathol
univers
korea
fulli
accredit
korean
associ
laboratori
anim
mice
experiment
procedur
conduct
studi
follow
guidelin
institut
anim
care
use
committe
cathol
univers
korea
approv
experiment
design
toxic
assess
follow
guidelin
nonclin
evalu
biopharmaceut
ministri
food
drug
safeti
evalu
toxic
ssrna
nanostructur
adjuv
mice
randomli
distribut
six
group
male
femal
mice
group
studi
use
sex
complianc
guidelin
proteinbas
vaccin
candid
middl
east
respiratori
syndrom
coronaviru
merscov
spike
protein
express
insect
cell
mer
protein
obtain
intern
vaccin
institut
seoul
korea
six
group
involv
studi
treat
follow
group
pbscontrol
group
group
mer
protein
group
ssrna
nanostructur
adjuv
group
mer
protein
ssrna
nanostructur
adjuv
lowdos
group
group
mer
protein
ssrna
nanostructur
adjuv
highdos
group
group
mer
protein
ssrna
nanostructur
adjuv
recoveri
group
anim
intramuscularli
immun
three
time
volum
everi
week
blood
collect
day
everi
immun
group
sacrif
day
last
immun
also
investig
group
recoveri
anoth
week
last
immun
assess
longlast
delay
revers
toxic
effect
accord
guidelin
protein
ssrna
dose
use
immun
lower
use
previou
studi
group
design
immun
schedul
shown
figur
separ
vivo
experi
conduct
analyz
immunolog
respons
group
aforement
design
five
femal
mice
group
group
immun
week
earlier
group
mice
sacrif
day
mice
group
sacrif
day
last
immun
group
sacrif
week
last
immun
posit
control
ige
analysi
eight
femal
mice
administ
dncb
everi
day
week
sacrif
week
last
treatment
dncb
dissolv
mixtur
aceton
oliv
oil
hair
anim
remov
day
dncb
appli
back
use
dose
anim
monitor
bodi
weight
food
intak
everi
week
end
studi
mice
anesthet
isofluran
blood
sampl
obtain
abdomin
aorta
mice
sacrif
one
mous
group
die
one
day
first
immun
unknown
reason
blood
sampl
collect
tube
contain
anticoagul
ethylenediaminetetraacet
acid
follow
hematolog
paramet
measur
procyt
dx
hematolog
analyz
idexx
usa
total
erythrocyt
count
rbc
hemoglobin
concentr
hgb
hematocrit
hct
mean
cell
volum
mcv
mean
cell
hemoglobin
mch
mean
cell
hemoglobin
concentr
mchc
platelet
plt
total
leucocyt
count
wbc
differenti
wbc
neutrophil
lymphocyt
monocyt
eosinophil
basophil
serum
sampl
obtain
centrifug
blood
sampl
g
min
follow
biochemistri
paramet
measur
mindray
chemic
analyz
mindray
shenzhen
china
alanin
aminotransferas
alt
aspart
aminotransferas
ast
total
cholesterol
tchol
triglycerid
tg
glucos
high
densiti
lipoprotein
cholesterol
hdl
low
densiti
lipoprotein
cholesterol
ldl
blood
urea
nitrogen
bun
creatinin
total
protein
tp
albumin
albumintoglobulin
ratio
ag
immedi
mice
sacrif
sever
organ
liver
kidney
spleen
thymu
lung
heart
lymph
node
muscl
brain
testi
remov
mice
examin
macroscop
weigh
organ
weight
rel
termin
bodi
weight
calcul
organ
fix
neutral
buffer
formalin
histopatholog
examin
testi
fix
bouin
solut
fix
organ
process
paraffin
embed
paraffin
section
stain
hematoxylin
eosin
h
e
microscop
featur
organ
mice
control
highdos
group
examin
experienc
pathologist
light
microscop
leica
hamburg
germani
serum
sampl
prepar
centrifug
g
min
last
collect
blood
sampl
group
store
level
total
serum
ige
measur
use
mous
enzymelink
immunosorb
assay
kit
bethyl
laboratori
inc
tx
usa
step
perform
accord
manufactur
instruct
ige
concentr
determin
base
absorb
nm
detect
micropl
reader
promega
wi
usa
serum
sampl
prepar
centrifug
g
min
last
collect
blood
sampl
group
store
level
antinuclear
antibodi
measur
use
mous
antinuclear
antibodi
igg
elisa
kit
mybiosourc
inc
ca
usa
step
perform
accord
manufactur
instruct
serum
sampl
prepar
centrifug
g
min
last
collect
blood
sampl
group
store
concentr
analyz
sampl
use
magnet
screen
assay
kit
r
system
inc
mn
usa
accord
manufactur
instruct
surfac
stain
splenocyt
isol
immun
cell
spleen
muscl
lymph
node
tissu
stain
min
room
temperatur
antibodi
follow
protein
clone
ebiosci
clone
biolegend
ca
usa
clone
bd
bioscienc
clone
invitrogen
ca
usa
clone
invitrogen
clone
mel
bd
bioscienc
clone
bio
legend
clone
invitrogen
clone
bd
bioscienc
clone
ebiosci
cell
fix
paraformaldehyd
analyz
use
fac
canto
ii
flow
cytomet
bd
bioscienc
nj
usa
data
analyz
use
flowjo
softwar
treestar
usa
oneway
analysi
varianc
use
assess
signific
differ
among
treatment
group
signific
effect
identifi
tukey
honestli
signific
differ
test
bonferroni
use
compar
multipl
group
mean
addit
histomorphometr
valu
express
mean
standard
deviat
sd
multiplecomparison
test
differ
treatment
group
conduct
signific
deviat
varianc
homogen
detect
use
leven
test
nonparametr
htest
conduct
signific
differ
detect
htest
utest
conduct
posthoc
analysi
statist
analys
conduct
use
spss
window
releas
spss
inc
il
usa
assess
signific
differ
two
group
student
ttest
use
differ
consid
signific
p
investig
toxic
ssrna
nanostructur
adjuv
measur
viabil
treat
cell
liver
lungderiv
tumor
cell
line
respect
well
human
skinderiv
normal
cell
line
mtt
assay
previous
inject
mice
ssrna
nanostructur
adjuv
increas
immun
respons
base
concentr
treat
cell
variou
concentr
ssrna
nanostructur
adjuv
h
ssrna
affect
cell
viabil
concentr
test
tumor
cell
line
figur
b
normal
human
cell
line
figur
howev
poli
c
posit
control
show
toxic
normal
cell
line
figur
furthermor
poli
c
induc
higher
proinflammatori
cytokin
ssrna
nanostructur
adjuv
raw
cell
mous
macrophag
cell
line
figur
detail
supplementari
method
indic
poli
c
may
stimul
stronger
inflamm
respons
compar
ssrna
nanostructur
adjuv
design
vivo
toxic
test
base
protocol
shown
figur
describ
detail
materi
method
section
inject
ssrna
nanostructur
adjuv
andor
mer
protein
observ
behavior
symptom
treat
mice
specif
problem
found
inject
male
femal
mice
compar
healthi
control
group
data
shown
extern
bodi
weight
figur
food
intak
figur
measur
critic
toxic
sign
experiment
anim
everi
week
follow
receipt
anim
signific
chang
found
weight
h
food
intak
male
femal
mice
among
group
therefor
anim
administ
ssrna
nanostructur
adjuv
formul
mer
protein
even
high
ssrna
concentr
show
specif
toxic
symptom
hematolog
result
includ
hematopoiesi
leukopoiesisassoci
paramet
summar
tabl
statist
signific
chang
hematolog
data
eg
hgb
hct
mcv
mch
mchc
wbc
male
femal
small
magnitud
within
accept
rang
therefor
differ
consid
relat
toxic
ssrna
nanostructur
adjuv
wbc
differenti
show
percentag
neutrophil
significantli
decreas
male
femal
comparison
male
mice
show
signific
increas
percentag
lymphocyt
rel
control
valu
percentag
monocyt
eosinophil
significantli
increas
male
return
normal
level
signific
treatmentrel
chang
found
paramet
test
male
femal
group
treat
ssrna
nanostructur
adjuv
serum
biochemistri
result
summar
tabl
serum
biochem
analysi
reveal
ast
level
significantli
decreas
male
compar
bun
level
significantli
decreas
male
increas
femal
comparison
creatinin
level
lower
compar
sex
small
signific
chang
tp
albumin
ag
ratio
glucos
ldl
observ
one
sex
hdl
level
high
male
mice
low
femal
mice
group
consid
reflect
transient
chang
concentrationdepend
phenomenon
tg
level
significantli
chang
male
femal
compar
respect
control
group
data
absolut
rel
organ
weight
summar
tabl
tabl
absolut
liver
weight
male
femal
significantli
higher
respect
control
group
rel
liver
weight
significantli
decreas
male
increas
femal
comparison
respect
control
group
absolut
rel
spleen
weight
male
femal
significantli
higher
compar
absolut
lung
weight
femal
higher
compar
furthermor
rel
lung
weight
significantli
decreas
male
increas
femal
comparison
meanwhil
kidney
weight
male
femal
higher
addit
small
sporad
weight
chang
brain
heart
testi
found
male
signific
weight
chang
organ
found
femal
interestingli
absolut
rel
thymu
weight
male
significantli
lower
compar
respect
control
group
wherea
signific
differ
found
thymu
weight
among
group
femal
although
find
regard
toxicolog
irrelev
lack
remark
histopatholog
correl
studi
necessari
confirm
understand
mechan
underli
sexrel
differ
thymu
weight
liver
typic
organ
studi
assess
toxic
also
lung
kidney
inject
site
immunerel
organ
spleen
thymu
stain
h
e
observ
local
system
toxic
includ
cellular
damag
inflammatori
cell
infiltr
associ
ssrna
nanostructur
adjuv
figur
male
femal
signific
doserel
damag
liver
lung
appar
highdos
group
mer
protein
ssrna
adjuv
compar
renal
involv
rel
common
autoimmun
diseas
studi
observ
histolog
chang
involv
kidney
damag
sex
intramuscularinject
site
also
regular
appear
importantli
thymu
spleen
serv
immunolog
organ
show
treatmentrel
toxic
identifi
involv
ssrna
nanostructur
adjuv
autoimmun
serum
level
ige
antinuclear
antibodi
measur
mice
immun
ssrna
nanostructur
adjuv
serum
ige
antibodi
mice
examin
use
mous
ige
elisa
kit
figur
posit
control
group
dncb
use
induc
allergi
mice
result
robust
ige
antibodi
product
detect
group
except
dncb
group
serum
concentr
antinuclear
antibodi
treat
mice
also
examin
use
antinuclear
antibodi
igg
elisa
kit
signific
induct
antinuclear
antibodi
product
observ
group
treat
ssrna
nanostructur
adjuv
compar
pbstreat
control
group
figur
measur
level
inflammationassoci
cytokin
signific
differ
found
level
proinflammatori
cytokin
group
examin
studi
figur
interestingli
product
antiinflammatori
cytokin
slightli
higher
ssrnatreat
group
group
figur
howev
level
recoveri
group
sacrif
two
week
later
decreas
compar
level
found
assess
immun
cell
activ
ssrna
nanostructur
adjuv
flow
cytometr
analysi
perform
use
splenocyt
immun
mice
cell
cell
indic
effector
memori
cell
rapidli
differenti
effector
cell
reexposur
antigen
splenocyt
show
statist
signific
differ
cell
group
figur
b
slightli
higher
cell
frequenc
versu
group
suggest
mice
prime
next
antigen
exposur
contrast
ssrna
nanostructur
adjuv
appear
activ
apc
includ
dc
macrophag
figur
recent
develop
ssrna
nanostructur
adjuv
use
crpv
igr
iresderiv
rna
found
function
immun
stimul
stimul
balanc
respons
mer
protein
moreov
ssrna
nanostructur
adjuv
show
synergist
effect
alum
increas
humor
cellular
immun
respons
although
alum
popularli
use
adjuv
human
clinic
vaccin
usual
induc
profound
respons
humor
immun
respons
along
produc
antibodi
wherea
stimul
respons
cellular
immun
respons
sometim
trigger
autoimmun
respons
previou
result
prove
crpv
igr
iresderiv
ssrna
nanostructur
adjuv
could
function
ideal
vaccin
adjuv
support
weak
alum
nonetheless
safeti
well
investig
yet
therefor
object
present
studi
perform
comprehens
investig
gener
toxic
profil
immunologicaltox
result
ssrna
nanostructur
adjuv
vitro
cytotox
studi
use
liver
lungderiv
cell
line
test
toxic
repres
target
organ
portal
entri
toxic
liver
detoxif
site
moreov
also
use
human
normal
cell
line
test
toxic
toxin
resist
tumor
cell
line
result
ssrna
nanostructur
adjuv
elicit
cellular
toxic
test
cell
line
even
increas
ssrna
concentr
higher
use
increas
immun
respons
previous
overcom
limit
vitro
studi
confirm
gener
toxic
immunolog
toxic
ssrna
nanostructur
adjuv
vivo
data
indic
ssrna
nanostructur
adjuv
formul
mer
protein
caus
treatmentrel
signific
alter
clinic
condit
growth
food
intak
sinc
broad
rang
toxic
injuri
begin
indol
often
asymptomat
featur
progress
organ
failur
addit
perform
hematolog
histolog
test
indic
system
advers
effect
test
materi
follow
necropsi
hematolog
analysi
show
decreas
neutrophil
increas
lymphocyt
seen
recoveri
group
male
femal
seem
typic
immun
respons
reflect
increas
b
cell
cell
typic
vaccin
immunizationderiv
respons
hematolog
paramet
treatment
group
show
signific
chang
within
physiolog
normal
rang
indic
ssrna
nanostructur
adjuv
affect
hematopoiesi
leukopoiesi
addit
doserel
signific
chang
observ
serum
biochem
paramet
test
notic
increas
alt
ast
level
repres
liver
toxic
found
among
group
male
femal
bun
creatinin
level
relat
renal
function
show
littl
chang
sex
signific
differ
fatti
liver
marker
tg
consid
relat
toxic
observ
chang
within
accept
rang
chang
marker
sporad
concentrationdepend
consid
reflect
toxic
chang
due
ssrna
nanostructur
adjuv
importantli
organ
weight
histolog
examin
major
organ
liver
kidney
lung
spleen
thymu
intramuscularinject
site
caus
toxicolog
signific
chang
involv
treatment
ssrna
nanostructur
adjuv
collect
contrast
poli
c
caus
sever
damag
kidney
spleen
ssrna
nanostructur
adjuv
induc
organ
injuri
male
femal
alum
commonli
use
adjuv
clinic
vaccin
field
sometim
induc
high
ige
level
associ
macrophag
myofasc
granuloma
format
allerg
reaction
ige
also
highli
elev
system
lupu
erythematosu
autoimmun
diseas
also
antinuclear
antibodi
recogn
self
nonself
bind
nucleu
one
cell
unlik
convent
antibodi
bind
foreign
antigen
viral
bacteri
antigen
vertebr
commonli
express
antinuclear
antibodi
low
level
wherea
rel
high
concentr
antinuclear
antibodi
indic
induct
autoimmun
diseas
studi
ssrna
nanostructur
adjuv
caus
signific
induct
serum
ige
antinuclear
antibodi
indic
ssrna
nanostructur
adjuv
pose
risk
autoimmun
inflammationassoci
cytokin
includ
monocyt
chemoattract
recruit
monocyt
infect
induc
inflamm
induc
inflamm
activ
lymphocyt
leukocyt
produc
monocyt
macrophag
play
import
role
inflammatori
regul
promot
synthesi
acutephas
protein
crp
produc
site
inflamm
overexpress
proinflammatori
cytokin
may
caus
excess
inflamm
autoimmun
diseas
studi
statist
signific
differ
level
proinflammatori
cytokin
among
group
particular
level
associ
autoimmun
higher
ssrnatreat
group
pbstreat
group
figur
support
possibl
ssrna
nanostructur
adjuv
induc
autoimmun
consist
data
serum
level
ige
antinuclear
antibodi
shown
figur
interestingli
level
ssrna
nanostructur
adjuv
group
compar
control
group
recoveri
group
slightli
increas
figur
may
counteract
induct
proinflammatori
cytokin
regardless
signific
increas
day
ssrna
treatment
howev
need
studi
reveal
complic
relationship
pro
antiinflammatori
cytokin
treatment
ssrna
nonstructur
adjuv
taken
togeth
signific
differ
found
proinflammatori
cytokin
level
among
group
also
level
return
normal
level
recoveri
group
indic
ssrna
nanostructur
adjuv
immunolog
toxic
statist
signific
differ
cell
found
splenocyt
group
contrast
observ
adjuv
dc
frequenc
ssrna
nanostructur
adjuvanttr
group
higher
control
spleen
least
partli
associ
higher
neutrophil
level
hematolog
analysi
vivo
toxic
studi
tabl
increas
dc
activ
found
compar
control
group
figur
accord
previou
data
show
ssrna
nanostructur
adjuv
transient
trigger
dc
activ
inject
site
may
caus
sacrif
mice
first
day
last
immun
dc
activ
earli
event
vaccin
inject
frequenc
dc
recoveri
group
return
level
found
control
group
figur
sinc
short
immun
durat
observ
without
toxicolog
differ
organ
weight
histopatholog
consid
ssrna
nanostructur
adjuv
elicit
immunolog
toxic
moreov
drain
lymph
node
signific
differ
occur
group
term
dc
macrophag
data
shown
data
indic
ssrna
nanostructur
adjuv
perform
success
safe
adjuv
previous
ssrna
nanostructur
adjuv
test
studi
shown
effect
elicit
immun
enhanc
mice
nonhuman
primat
base
balanc
respons
studi
show
adjuv
caus
weight
loss
abnorm
behavior
mice
immun
even
high
dose
moreov
increas
hematolog
biochem
paramet
chang
histopatholog
pattern
compar
control
group
addit
ssrna
nanostructur
adjuv
promot
sustain
proinflammatori
cytokin
excess
immun
cell
activ
long
time
indic
quickli
disappear
immun
instead
result
appear
reflect
effect
hitandrun
strategi
stimul
immun
respons
therefor
ssrna
nanostructur
function
safe
adjuv
high
vaccin
efficaci
